Đang chuẩn bị liên kết để tải về tài liệu:
Tumor mutational burden is associated with poor outcomes in diffuse glioma

Tumor mutational burden (TMB) is a potential biomarker for immune checkpoint therapy and prognosis. The impact of TMB on clinical outcomes and the correlation coefficient between exome sequencing and targeted sequencing in glioma have not yet been explored. | Tumor mutational burden is associated with poor outcomes in diffuse glioma